Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02600819 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis
A Phase 3 study of HIV-1-infection, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT02600819 is a Phase 3 study of HIV-1-infection that has completed, run by Gilead Sciences. The registered enrollment target is 55 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02600819, a Phase 3 study of HIV-1-infection, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV-1) infected adults with end-stage renal disease (ESRD) on chronic hemodialysis (HD).
Conditions Studied
Interventions
- DRUG B/F/TAF
- DRUG E/C/F/TAF
Study Locations (20)
Florida
- Midway Immunology & Research Center, LLC - Ft. Pierce
- Infectious Disease Consultants, M.D., P.A. d/b/a Orlando Immunology Center - Orlando
- Triple O Research Institute PA - West Palm Beach
Georgia
- Medical College of Georgia - Augusta
- Infectious Disease Specialists of Atlanta - Decatur
- Mercer University School of Medicine - Macon
North Carolina
- University of North Carolina at Chapel Hill / UNC School of Medicine - Chapel Hill
- Duke University - Durham
- Wake Forest University Baptist Medical Center - Winston-Salem
Texas
- North Texas Infectious Diseases Consultants - Dallas
- Trinity Health and Wellness Center - Fort Worth
- Gordon E. Crofoot MD PA - Houston
California
- Peter J Ruane MD Inc - Los Angeles
- University of California Davis - Sacramento
Ohio
- University of Cincinnati Med Center - Cincinnati
- MetroHealth Medical Center IRB - Cleveland
Massachusetts
- The Research Institute - Springfield
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02600819
The ClinicalTrials.gov registry entry for NCT02600819 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (84% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 2 interventions - of which B/F/TAF is the first listed.
NCT02600819 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Georgia, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02600819 about?
NCT02600819 is a clinical study titled "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis". The primary objective of this study is to evaluate the safety and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV-1) infected adults with end-stage renal disease (ESRD) on chronic hemodialysis (...
What is the current status of trial NCT02600819?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 55 participants. The study started on 2015-12-14. Estimated completion is 2019-10-15.
What conditions does trial NCT02600819 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT02600819?
The interventions under investigation include: B/F/TAF (DRUG), E/C/F/TAF (DRUG).
Who is sponsoring clinical trial NCT02600819?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02600819 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
ACTIVE NOT RECRUITING · Phase 3
-
Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1
ACTIVE NOT RECRUITING · Phase 3
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)
ACTIVE NOT RECRUITING · Phase 3
-
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
ACTIVE NOT RECRUITING · Phase 3
-
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
ACTIVE NOT RECRUITING · Phase 3
-
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.